Cellectis has patented a method for engineering T cells with Chimeric Antigen Receptors (CARs) targeting CD123-expressing cells, for treating lymphomas and leukemia. The CAR includes specific sequences from a CD123 monoclonal antibody, enhancing immune cell specificity. GlobalData’s report on Cellectis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cellectis, CAR-T cell based therapies was a key innovation area identified from patents. Cellectis's grant share as of February 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric antigen receptor (car) for cd123-positive cancer treatment
A recently granted patent (Publication Number: US11919961B2) outlines an ex vivo method for engineering T cells suitable for allogenic immunotherapy treatment of pre-malignant or malignant cancer conditions characterized by CD123-expressing cells. The method involves inactivating genes encoding T-cell receptor components and introducing a CD123 specific chimeric antigen receptor (CAR) into the T cell. The CAR includes specific sequences from a monoclonal anti-CD123 antibody, along with other structural components for effective targeting and signaling within the cell.
Furthermore, the patent details additional aspects of the method, such as the use of rare-cutting endonucleases for gene inactivation, suppression of major histocompatibility complex proteins, and reduction of immune checkpoint proteins in the engineered T cells. The engineered T cells expressing the CD123 specific CAR can be used in allogenic immunotherapy treatments for various types of leukemia and lymphoma. Additionally, the engineered T cells can be mutated to confer resistance to immune suppressive, chemotherapy, or anti-cancer drugs, enhancing their effectiveness in combating cancer. This patent provides a comprehensive guide for the development and application of engineered T cells in cancer immunotherapy, offering potential advancements in treatment strategies for patients in need.
To know more about GlobalData’s detailed insights on Cellectis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
